In conclusion, high baseline plasma AREG levels predicted worse PFS in patients with RAS/BRAF wild-type metastatic colorectal cancer treated with palliative first-line cetuximab plus FOLFIRI chemotherapy, but not with non-EGFR-directed second-line treatment. Here, BRAF is linked to metastatic colorectal cancer.